Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Syncytial Virus Infections | 27 | 2024 | 200 | 6.650 |
Why?
|
| Influenza, Human | 34 | 2025 | 374 | 4.580 |
Why?
|
| Respiratory Tract Infections | 24 | 2024 | 266 | 4.370 |
Why?
|
| Respiratory Syncytial Virus, Human | 23 | 2024 | 155 | 4.300 |
Why?
|
| Hospitalization | 23 | 2024 | 418 | 2.130 |
Why?
|
| Infant | 54 | 2025 | 2244 | 1.940 |
Why?
|
| Child, Preschool | 50 | 2025 | 1748 | 1.850 |
Why?
|
| HIV Infections | 29 | 2024 | 5097 | 1.660 |
Why?
|
| South Africa | 77 | 2025 | 7596 | 1.640 |
Why?
|
| Influenza Vaccines | 7 | 2025 | 144 | 1.540 |
Why?
|
| Child | 39 | 2025 | 2242 | 1.430 |
Why?
|
| Humans | 91 | 2025 | 14537 | 1.430 |
Why?
|
| Virus Diseases | 4 | 2023 | 55 | 1.170 |
Why?
|
| Coinfection | 13 | 2019 | 276 | 1.120 |
Why?
|
| Aged | 26 | 2025 | 1740 | 1.020 |
Why?
|
| Male | 44 | 2025 | 6754 | 0.990 |
Why?
|
| Adolescent | 34 | 2025 | 2985 | 0.970 |
Why?
|
| Female | 51 | 2025 | 9103 | 0.930 |
Why?
|
| Middle Aged | 33 | 2025 | 3601 | 0.910 |
Why?
|
| Population Surveillance | 9 | 2019 | 325 | 0.900 |
Why?
|
| Young Adult | 28 | 2025 | 2498 | 0.890 |
Why?
|
| Cost of Illness | 8 | 2024 | 167 | 0.850 |
Why?
|
| Infant, Newborn | 21 | 2025 | 1479 | 0.850 |
Why?
|
| Prevalence | 16 | 2024 | 1192 | 0.830 |
Why?
|
| Adult | 38 | 2025 | 5913 | 0.810 |
Why?
|
| Prospective Studies | 26 | 2025 | 1160 | 0.810 |
Why?
|
| Communicable Diseases | 1 | 2023 | 62 | 0.790 |
Why?
|
| Vaccination | 12 | 2025 | 365 | 0.750 |
Why?
|
| Seasons | 14 | 2024 | 154 | 0.710 |
Why?
|
| Sentinel Surveillance | 7 | 2024 | 115 | 0.700 |
Why?
|
| Viruses | 6 | 2022 | 47 | 0.600 |
Why?
|
| Incidence | 12 | 2025 | 685 | 0.540 |
Why?
|
| Diarrhea | 5 | 2017 | 76 | 0.500 |
Why?
|
| Aged, 80 and over | 11 | 2025 | 468 | 0.500 |
Why?
|
| Global Health | 5 | 2023 | 193 | 0.450 |
Why?
|
| Pneumococcal Infections | 3 | 2023 | 299 | 0.410 |
Why?
|
| Orthomyxoviridae | 6 | 2020 | 33 | 0.400 |
Why?
|
| Rhinovirus | 3 | 2019 | 23 | 0.390 |
Why?
|
| Epidemics | 2 | 2024 | 65 | 0.380 |
Why?
|
| Respiratory Syncytial Viruses | 3 | 2023 | 28 | 0.380 |
Why?
|
| Risk Factors | 9 | 2024 | 1475 | 0.370 |
Why?
|
| Rotavirus Infections | 3 | 2017 | 46 | 0.350 |
Why?
|
| Rotavirus Vaccines | 3 | 2017 | 53 | 0.350 |
Why?
|
| Acute Disease | 5 | 2017 | 105 | 0.340 |
Why?
|
| Cost-Benefit Analysis | 6 | 2023 | 253 | 0.320 |
Why?
|
| Epidemiological Monitoring | 4 | 2019 | 45 | 0.310 |
Why?
|
| Pilot Projects | 3 | 2024 | 179 | 0.300 |
Why?
|
| Cohort Studies | 8 | 2024 | 967 | 0.280 |
Why?
|
| Picornaviridae Infections | 2 | 2019 | 18 | 0.270 |
Why?
|
| Caliciviridae Infections | 2 | 2017 | 11 | 0.270 |
Why?
|
| Streptococcus pneumoniae | 6 | 2023 | 336 | 0.260 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 563 | 0.260 |
Why?
|
| Nasopharynx | 8 | 2023 | 151 | 0.260 |
Why?
|
| Rural Population | 5 | 2021 | 654 | 0.260 |
Why?
|
| Asymptomatic Infections | 2 | 2025 | 34 | 0.240 |
Why?
|
| Corynebacterium diphtheriae | 1 | 2025 | 9 | 0.240 |
Why?
|
| Pneumonia, Pneumococcal | 3 | 2015 | 100 | 0.230 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2025 | 198 | 0.220 |
Why?
|
| Intention | 1 | 2023 | 23 | 0.210 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2015 | 529 | 0.210 |
Why?
|
| Hospital Mortality | 5 | 2023 | 95 | 0.210 |
Why?
|
| Costs and Cost Analysis | 1 | 2023 | 42 | 0.210 |
Why?
|
| Whooping Cough | 1 | 2023 | 36 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 1 | 2025 | 293 | 0.200 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 90 | 0.190 |
Why?
|
| Tuberculosis | 2 | 2019 | 543 | 0.190 |
Why?
|
| Models, Statistical | 2 | 2021 | 55 | 0.180 |
Why?
|
| Pregnancy | 8 | 2023 | 1862 | 0.180 |
Why?
|
| Housing | 1 | 2021 | 24 | 0.180 |
Why?
|
| Pandemics | 5 | 2023 | 296 | 0.180 |
Why?
|
| Air Pollution, Indoor | 1 | 2021 | 13 | 0.180 |
Why?
|
| Urban Health | 1 | 2021 | 78 | 0.180 |
Why?
|
| Rural Health | 1 | 2021 | 118 | 0.170 |
Why?
|
| Genotype | 3 | 2017 | 442 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 260 | 0.170 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 253 | 0.170 |
Why?
|
| History, 21st Century | 4 | 2025 | 42 | 0.170 |
Why?
|
| Seroepidemiologic Studies | 4 | 2023 | 109 | 0.160 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 5 | 0.160 |
Why?
|
| Absenteeism | 1 | 2019 | 10 | 0.160 |
Why?
|
| Life Expectancy | 1 | 2019 | 31 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 43 | 0.160 |
Why?
|
| Metapneumovirus | 2 | 2016 | 30 | 0.150 |
Why?
|
| Community Health Services | 1 | 2018 | 58 | 0.140 |
Why?
|
| Pneumococcal Vaccines | 2 | 2023 | 278 | 0.140 |
Why?
|
| Rotavirus | 1 | 2017 | 29 | 0.140 |
Why?
|
| Norovirus | 1 | 2017 | 5 | 0.140 |
Why?
|
| Immunization Programs | 2 | 2017 | 81 | 0.140 |
Why?
|
| Bacteremia | 2 | 2014 | 79 | 0.130 |
Why?
|
| Public Health Surveillance | 4 | 2019 | 52 | 0.130 |
Why?
|
| Kenya | 3 | 2024 | 183 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 77 | 0.130 |
Why?
|
| Sapovirus | 1 | 2016 | 6 | 0.130 |
Why?
|
| Respirovirus | 1 | 2015 | 4 | 0.130 |
Why?
|
| Influenza A virus | 1 | 2016 | 28 | 0.130 |
Why?
|
| Anti-Retroviral Agents | 3 | 2021 | 551 | 0.130 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2015 | 10 | 0.130 |
Why?
|
| Influenza B virus | 1 | 2016 | 42 | 0.130 |
Why?
|
| Disease Outbreaks | 2 | 2013 | 111 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2015 | 39 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2017 | 132 | 0.120 |
Why?
|
| Pneumovirus Infections | 1 | 2015 | 7 | 0.120 |
Why?
|
| Hospitals, Rural | 1 | 2015 | 11 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 23 | 0.120 |
Why?
|
| Bronchopneumonia | 1 | 2015 | 11 | 0.120 |
Why?
|
| Developing Countries | 2 | 2017 | 400 | 0.120 |
Why?
|
| Vaccines, Conjugate | 1 | 2015 | 171 | 0.110 |
Why?
|
| HIV-1 | 3 | 2012 | 1260 | 0.110 |
Why?
|
| Viral Fusion Proteins | 1 | 2013 | 13 | 0.110 |
Why?
|
| Selection, Genetic | 1 | 2013 | 31 | 0.110 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 60 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1422 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2021 | 149 | 0.110 |
Why?
|
| Models, Theoretical | 3 | 2019 | 80 | 0.110 |
Why?
|
| Patient Compliance | 3 | 2009 | 120 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2015 | 104 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2014 | 175 | 0.100 |
Why?
|
| Urban Population | 3 | 2021 | 257 | 0.100 |
Why?
|
| Measles | 1 | 2013 | 36 | 0.100 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 23 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2012 | 54 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2019 | 480 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2013 | 56 | 0.100 |
Why?
|
| Age Distribution | 3 | 2024 | 107 | 0.100 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 284 | 0.100 |
Why?
|
| Carrier State | 2 | 2023 | 92 | 0.090 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 324 | 0.090 |
Why?
|
| Phylogeny | 3 | 2017 | 231 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2021 | 133 | 0.090 |
Why?
|
| Propylene Glycols | 1 | 2009 | 3 | 0.080 |
Why?
|
| Phosphates | 1 | 2009 | 10 | 0.080 |
Why?
|
| Glycerol | 1 | 2009 | 8 | 0.080 |
Why?
|
| Cellulose | 1 | 2009 | 21 | 0.080 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2009 | 16 | 0.080 |
Why?
|
| Fever | 2 | 2019 | 26 | 0.080 |
Why?
|
| Herpesvirus 2, Human | 1 | 2009 | 43 | 0.080 |
Why?
|
| Contraceptive Devices, Female | 1 | 2009 | 30 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2019 | 799 | 0.080 |
Why?
|
| Herpes Genitalis | 1 | 2009 | 43 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2009 | 32 | 0.080 |
Why?
|
| World Health Organization | 2 | 2020 | 137 | 0.080 |
Why?
|
| Age Factors | 2 | 2024 | 370 | 0.080 |
Why?
|
| Monte Carlo Method | 2 | 2019 | 11 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 385 | 0.070 |
Why?
|
| United States | 2 | 2021 | 132 | 0.070 |
Why?
|
| Community Health Centers | 1 | 2007 | 9 | 0.070 |
Why?
|
| Occupations | 1 | 2007 | 13 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 57 | 0.070 |
Why?
|
| Australia | 2 | 2018 | 48 | 0.070 |
Why?
|
| Feces | 2 | 2017 | 30 | 0.070 |
Why?
|
| Comorbidity | 2 | 2019 | 188 | 0.070 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2007 | 103 | 0.070 |
Why?
|
| Algorithms | 2 | 2021 | 106 | 0.070 |
Why?
|
| Mass Screening | 2 | 2019 | 245 | 0.060 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2009 | 472 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 256 | 0.060 |
Why?
|
| Time Factors | 2 | 2019 | 507 | 0.060 |
Why?
|
| Corynebacterium Infections | 1 | 2025 | 5 | 0.060 |
Why?
|
| Diphtheria | 1 | 2025 | 16 | 0.060 |
Why?
|
| Singapore | 1 | 2024 | 3 | 0.060 |
Why?
|
| New Zealand | 1 | 2024 | 8 | 0.060 |
Why?
|
| Viral Interference | 1 | 2024 | 2 | 0.060 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2025 | 135 | 0.060 |
Why?
|
| Molecular Epidemiology | 2 | 2014 | 47 | 0.060 |
Why?
|
| Health Expenditures | 1 | 2024 | 39 | 0.060 |
Why?
|
| Linear Models | 1 | 2024 | 83 | 0.050 |
Why?
|
| Bacterial Load | 2 | 2014 | 32 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 171 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 263 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2024 | 115 | 0.050 |
Why?
|
| Bordetella pertussis | 1 | 2023 | 29 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 150 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 435 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2022 | 46 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 142 | 0.050 |
Why?
|
| Markov Chains | 1 | 2021 | 22 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 109 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 411 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 106 | 0.050 |
Why?
|
| Computational Biology | 1 | 2021 | 44 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 53 | 0.050 |
Why?
|
| Cooking | 1 | 2021 | 7 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 262 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 217 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 1324 | 0.040 |
Why?
|
| HIV | 1 | 2023 | 380 | 0.040 |
Why?
|
| Cough | 1 | 2019 | 14 | 0.040 |
Why?
|
| Child, Hospitalized | 1 | 2019 | 26 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 16 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2019 | 21 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2009 | 43 | 0.040 |
Why?
|
| Inpatients | 1 | 2019 | 30 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 38 | 0.040 |
Why?
|
| Data Collection | 1 | 2019 | 86 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 74 | 0.040 |
Why?
|
| Prognosis | 1 | 2019 | 199 | 0.040 |
Why?
|
| Vietnam | 1 | 2018 | 13 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 47 | 0.030 |
Why?
|
| Critical Care | 1 | 2017 | 52 | 0.030 |
Why?
|
| Animals | 1 | 2019 | 1081 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2017 | 303 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 21 | 0.030 |
Why?
|
| Cross Protection | 1 | 2016 | 4 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 64 | 0.030 |
Why?
|
| Paramyxoviridae Infections | 1 | 2016 | 27 | 0.030 |
Why?
|
| Serotyping | 1 | 2015 | 66 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 18 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2015 | 22 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 2015 | 54 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 133 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 87 | 0.030 |
Why?
|
| Suburban Population | 1 | 2014 | 9 | 0.030 |
Why?
|
| Hospitals | 1 | 2015 | 103 | 0.030 |
Why?
|
| Mortality | 1 | 2015 | 104 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 2 | 0.030 |
Why?
|
| Egypt | 1 | 2013 | 4 | 0.030 |
Why?
|
| Guatemala | 1 | 2013 | 8 | 0.030 |
Why?
|
| Weather | 1 | 2013 | 7 | 0.030 |
Why?
|
| Bangladesh | 1 | 2013 | 17 | 0.030 |
Why?
|
| Thailand | 1 | 2013 | 26 | 0.030 |
Why?
|
| Climate | 1 | 2013 | 5 | 0.030 |
Why?
|
| China | 1 | 2013 | 21 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 54 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2015 | 265 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 181 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2013 | 24 | 0.030 |
Why?
|
| Pharynx | 1 | 2012 | 4 | 0.030 |
Why?
|
| Virus Cultivation | 1 | 2012 | 9 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2012 | 7 | 0.030 |
Why?
|
| Oropharynx | 1 | 2012 | 17 | 0.030 |
Why?
|
| Measles Vaccine | 1 | 2013 | 34 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2012 | 38 | 0.020 |
Why?
|
| Drug Resistance, Viral | 1 | 2012 | 278 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2009 | 21 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 38 | 0.020 |
Why?
|
| Vulva | 1 | 2009 | 2 | 0.020 |
Why?
|
| Cervix Uteri | 1 | 2009 | 22 | 0.020 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2009 | 24 | 0.020 |
Why?
|
| Administration, Intravaginal | 1 | 2009 | 50 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 2009 | 22 | 0.020 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2009 | 41 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 125 | 0.020 |
Why?
|
| AIDS Serodiagnosis | 1 | 2009 | 44 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 101 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2009 | 56 | 0.020 |
Why?
|
| Vagina | 1 | 2009 | 91 | 0.020 |
Why?
|
| Point-of-Care Systems | 1 | 2009 | 91 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 272 | 0.020 |
Why?
|
| Recreation | 1 | 2007 | 4 | 0.020 |
Why?
|
| Food Industry | 1 | 2007 | 11 | 0.020 |
Why?
|
| Program Development | 1 | 2007 | 32 | 0.020 |
Why?
|
| Tanzania | 1 | 2007 | 88 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2009 | 889 | 0.020 |
Why?
|